Pulmatrix | MedPath

Pulmatrix to Divest Phase 2-Ready Migraine Treatment and iSPERSE Technology Ahead of Cullgen Merger

7 days ago

• Pulmatrix plans to divest its clinical assets including PUR3100, a Phase 2-ready inhaled treatment for acute migraine, as part of its upcoming merger with Cullgen expected to close in June 2025. • The company's proprietary iSPERSE technology, which enables efficient pulmonary drug delivery with 146 granted patents, will also be divested as Pulmatrix transitions to focus on Cullgen's protein degradation platform. • First quarter 2025 financial results showed zero revenue (down from $5.9M in Q1 2024) with $7.7M cash on hand, which the company believes is sufficient to fund operations through the anticipated merger closing.

Cullgen Launches Phase 1 Trial of Novel Non-Opioid Pain Treatment Using Protein Degradation Technology

4 months ago

Cullgen Inc. has initiated Phase 1 dosing of CG001419, a first-in-class oral pan-TRK protein degrader designed to treat acute and chronic pain without the addiction risks associated with opioids. The randomized, placebo-controlled trial in Australia will evaluate the safety, tolerability, and pharmacokinetics of this innovative non-opioid, non-NSAID analgesic therapy.